Medical Industry Feature

Episodes 1-15 of 135

• 

  RestartResume

  Investigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO

  Medical Industry Feature

  Investigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO

  • 

    

    Christyn Edmundson, MD

    Peer

• 

  RestartResume

  From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice

  Medical Industry Feature

  From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Thomas Brannagan III, MD

    Peer

  • 

    

    Marcus Anthony Urey, MD

    Peer

• 

  RestartResume

  Investigating a gMG Therapy, Part 1: The MG-ADL Results

  Medical Industry Feature

  Investigating a gMG Therapy, Part 1: The MG-ADL Results

  • 

    

    Christyn Edmundson, MD

    Peer

• 

  RestartResume

  Investigating a gMG Therapy, Part 3: Results from the Extension Studies

  Medical Industry Feature

  Investigating a gMG Therapy, Part 3: Results from the Extension Studies

  • 

    

    Christyn Edmundson, MD

    Peer

• 

  RestartResume

  SCIg for Patient-Centric Care: Combining Experience with Innovation

  Medical Industry Feature

  SCIg for Patient-Centric Care: Combining Experience with Innovation

  • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Elena Perez, MD

    Peer

• 

  RestartResume

  The Role of APRIL in IgA Nephropathy

  Medical Industry Feature

  The Role of APRIL in IgA Nephropathy

• 

  RestartResume

  Unraveling Hereditary ATTR Amyloidosis: Key Variants and Clinical Insights

  Medical Industry Feature

  Unraveling Hereditary ATTR Amyloidosis: Key Variants and Clinical Insights

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Nitasha Sarswat, MD

    Peer

  • 

    

    Thomas Brannagan III, MD

    Peer

• 

  RestartResume

  Uncovering Unmet Needs in ATTR Amyloidosis

  Medical Industry Feature

  Uncovering Unmet Needs in ATTR Amyloidosis

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Nitasha Sarswat, MD

    Peer

• 

  RestartResume

  Best Practices for an Aesthetic Neurotoxin Approach

  Medical Industry Feature

  Best Practices for an Aesthetic Neurotoxin Approach

  • 

    

    Jean Carruthers, MD

    Peer

  • 

    

    Steve Yoelin, MD

    Peer

  • 

    

    Brandice Harrison, PA-C

    Peer

• 

  RestartResume

  Unraveling IgA Nephropathy Pathogenesis: APRIL and the Four-Hit Cascade

  Medical Industry Feature

  Unraveling IgA Nephropathy Pathogenesis: APRIL and the Four-Hit Cascade

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Sayna Norouzi, MD

    Peer

  • 

    

    Jared Hassler, MD

    Peer

• 

  RestartResume

  Unraveling IgA Nephropathy: Clinical Features and the Need for Early Diagnosis  

  Medical Industry Feature

  Unraveling IgA Nephropathy: Clinical Features and the Need for Early Diagnosis  

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Sayna Norouzi, MD

    Peer

  • 

    

    Jared Hassler, MD

    Peer

• 

  RestartResume

  Overcoming Vaccine Hesitancy: Persuasive Conversation Strategies and Tips

  Medical Industry Feature

  Overcoming Vaccine Hesitancy: Persuasive Conversation Strategies and Tips

• 

  RestartResume

  Expert Insights on Congenital Adrenal Hyperplasia Care From an Adult Endocrinologist

  Medical Industry Feature

  Expert Insights on Congenital Adrenal Hyperplasia Care From an Adult Endocrinologist

  • 

    

    Sara Lubitz, MD

    Peer

• 

  RestartResume

  Expert Insights on Adult Congenital Adrenal Hyperplasia Care

  Medical Industry Feature

  Expert Insights on Adult Congenital Adrenal Hyperplasia Care

  • 

    

    Sara Lubitz, MD

    Peer

• 

  RestartResume

  Improving Outcomes in hATTR-PN: The Role of Vigilant Symptom Assessment

  Medical Industry Feature

  Improving Outcomes in hATTR-PN: The Role of Vigilant Symptom Assessment

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Thomas Brannagan III, MD

    Peer

• 1
• 2
• 3
• …
• 8
• 9
• Next